4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6-(2-methoxyethyl)-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one | 1383377-34-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6-(2-methoxyethyl)-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one
• 英文别名: 4-[3-(4-fluorophenyl)-1-methylpyrazol-4-yl]-6-(2-methoxyethyl)-7H-pyrrolo[3,4-b]pyridin-5-one
• CAS: 1383377-34-1
• 化学式: C₂₀H₁₉FN₄O₂
• 分子量: 366.395
• InChiKey: RBEFIAUFQJWNSM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  60.2
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• COMPOUNDS FOR TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION
  申请人：Facio Intellectual Property B.V.

  公开号：EP3498278A1

  公开（公告）日：2019-06-19

  The present invention relates to compounds for the treatment of diseases related to DUX4 expression, such as muscular dystrophies, in this case facioscapulohumeral muscular dystrophy (FSHD). It also relates to use of such compounds, or to methods of use of such compounds.

  本发明涉及用于治疗与 DUX4 表达有关的疾病的化合物，例如肌肉萎缩症，在本例中为面肩肱肌萎缩症（FSHD）。本发明还涉及此类化合物的用途或使用方法。
• Compounds for treatment of diseases related to DUX4 expression
  申请人：Facio Intellectual Property B.V.

  公开号：US10973820B2

  公开（公告）日：2021-04-13

  The present invention relates to compounds for the treatment of diseases related to DUX4 expression, such as muscular dystrophies, wherein the disease is facioscapulohumeral muscular dystrophy (FSHD). It also relates to use of such compounds, or to methods of use of such compounds.

  本发明涉及用于治疗与DUX4表达有关的疾病的化合物，如肌肉萎缩症，其中该疾病为面肩肱肌营养不良症（FSHD）。本发明还涉及此类化合物的用途或使用方法。
• NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS
  申请人：Pfizer Inc.

  公开号：EP2654750B1

  公开（公告）日：2017-03-08
• [EN] CASEIN KINASE 1 INHIBITORS FOR USE IN THE TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION SUCH AS MUSCULAR DYSTROPHY AND CANCER<br/>[FR] INHIBITEURS DE LA CASÉINE KINASE 1 DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE MALADIES LIÉES À L'EXPRESSION DE DUX4 TELLES QUE LA DYSTROPHIE MUSCULAIRE ET LE CANCER
  申请人：FACIO INTELLECTUAL PROPERTY B V

  公开号：WO2020249717A1

  公开（公告）日：2020-12-17

  The present invention relates to casein kinase 1 inhibitors alone or in combination with p38 inhibitors for use in the treatment of diseases related to DUX4 expression, such as muscular dystrophies and cancer.